Apimeds Pharmaceuticals US Net Tangible Assets

Apimeds Pharmaceuticals US (APUS) currently reports a net tangible assets of $130M as of March 2026. That compares with $-1.8M in the prior-year period — up 7286.3% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's net tangible assets history and peer comparisons.

Apimeds Pharmaceuticals US's net tangible assets increased from $-1.8M to $130M — a 7286.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $130M in net tangible assets as of March 2026. That compares with $-1.8M in the prior-year period — up 7286.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.